JPWO2019189780A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019189780A5
JPWO2019189780A5 JP2019522350A JP2019522350A JPWO2019189780A5 JP WO2019189780 A5 JPWO2019189780 A5 JP WO2019189780A5 JP 2019522350 A JP2019522350 A JP 2019522350A JP 2019522350 A JP2019522350 A JP 2019522350A JP WO2019189780 A5 JPWO2019189780 A5 JP WO2019189780A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
amino acid
acid sequence
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019522350A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019189780A1 (ja
JP7342701B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2019/014044 external-priority patent/WO2019189780A1/ja
Publication of JPWO2019189780A1 publication Critical patent/JPWO2019189780A1/ja
Publication of JPWO2019189780A5 publication Critical patent/JPWO2019189780A5/ja
Application granted granted Critical
Publication of JP7342701B2 publication Critical patent/JP7342701B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019522350A 2018-03-30 2019-03-29 癌の治療及び/又は予防用医薬組成物 Active JP7342701B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018067453 2018-03-30
JP2018067453 2018-03-30
PCT/JP2019/014044 WO2019189780A1 (ja) 2018-03-30 2019-03-29 癌の治療及び/又は予防用医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2019189780A1 JPWO2019189780A1 (ja) 2021-02-12
JPWO2019189780A5 true JPWO2019189780A5 (https=) 2022-04-01
JP7342701B2 JP7342701B2 (ja) 2023-09-12

Family

ID=68062008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522350A Active JP7342701B2 (ja) 2018-03-30 2019-03-29 癌の治療及び/又は予防用医薬組成物

Country Status (9)

Country Link
US (1) US20210121562A1 (https=)
EP (1) EP3777888A4 (https=)
JP (1) JP7342701B2 (https=)
CN (1) CN111936164B (https=)
AU (2) AU2019242520B2 (https=)
BR (1) BR112020019935A2 (https=)
CA (1) CA3095719A1 (https=)
MX (1) MX2020009862A (https=)
WO (1) WO2019189780A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911926A2 (pt) * 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
WO2021182574A1 (ja) * 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
KR20220152309A (ko) * 2020-03-12 2022-11-15 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
CA3175277A1 (en) * 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3175137A1 (en) * 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4119159A4 (en) * 2020-03-12 2024-03-27 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
US20250228937A1 (en) * 2021-06-23 2025-07-17 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
MX2023014498A (es) * 2021-06-23 2024-01-25 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer.
WO2023008461A1 (ja) * 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び/又は予防のための医薬品
KR20240041917A (ko) * 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
CN117693363A (zh) * 2021-07-27 2024-03-12 东丽株式会社 用于癌的治疗和/或预防的药品
CA3232439A1 (en) * 2021-09-16 2023-03-23 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN114213534B (zh) * 2022-02-21 2022-06-03 南京佰抗生物科技有限公司 抗人PlGF鼠源单克隆抗体及应用
AU2023334696A1 (en) * 2022-08-30 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20250053841A (ko) * 2022-08-30 2025-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
CN115992142B (zh) * 2022-12-15 2023-10-13 徐州医科大学 与神经保护相关的hsa_circ_0000288及用途
MX2025006330A (es) * 2022-12-23 2025-07-01 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer
KR20240102594A (ko) 2022-12-26 2024-07-03 한국원자력연구원 백금족 원소가 도포된 니켈 스폰지 및 그 제조 방법
WO2024204325A1 (ja) 2023-03-28 2024-10-03 東レ株式会社 細胞膜タンパク質を検出する方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
PT2324842E (pt) * 2008-08-05 2015-07-21 Toray Industries Agente de indução de imunidade
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
US9115200B2 (en) * 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス,インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
EP2740794B1 (en) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PL2740793T3 (pl) 2011-08-04 2018-04-30 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
US9260513B2 (en) * 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び/又は予防用医薬組成物
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び/又は予防用医薬組成物
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び/又は予防用医薬組成物
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
AU2014303375B2 (en) * 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
AU2015209277B2 (en) 2014-01-22 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
CN105233291A (zh) * 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
ES2761861T3 (es) * 2015-01-21 2020-05-21 Univ Leland Stanford Junior Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas
CN109890417A (zh) * 2016-10-28 2019-06-14 东丽株式会社 癌的治疗和/或预防用药物组合物

Similar Documents

Publication Publication Date Title
JPWO2019189780A5 (https=)
KR102349056B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
Wang et al. ABBV-399, a c-Met antibody–drug conjugate that targets both MET–amplified and c-Met–overexpressing tumors, irrespective of MET pathway dependence
Guo et al. Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment
Nicolosi et al. Theranostic impact of NG2/CSPG4 proteoglycan in cancer
RU2013104830A (ru) Лечение рака при помощи направленных на мишень антител in vivo
RU2014138038A (ru) Фармацевтическая композиция для лечения профилактики рака
RU2014108044A (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
RU2014138040A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
EA201790547A1 (ru) Новые соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы
JP2013502913A5 (https=)
RU2012137503A (ru) Лекарственный препарат для лечения и/или профилактики рака
RU2013155455A (ru) Антитела для лечения раковых заболеваний, при которых эскспрессируется клаудин 6
RU2014138041A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2012137502A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2014111999A (ru) Антитела к C10RF32 и их применения для лечения рака
RU2014108045A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
RU2014108049A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
JP2018515137A5 (https=)
AU2011243958A1 (en) Molecules and methods of using same for treating ErbB/ErbB ligands associated diseases
JP2020522512A5 (https=)
Lu et al. Endosialin in cancer: expression patterns, mechanistic insights, and therapeutic approaches
JPWO2022270524A5 (https=)
Chen et al. Enhanced effect of radiofrequency ablation on HCC by siRNA-PD-L1-endostatin Co-expression plasmid delivered
JP2011524179A5 (https=)